secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0000950170-25-030392
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax Q4 Revuforj revenue $7.7M; net loss $94.2M; cash $692.4M
---------------------------------------------------------------

- Q4 2024 Revuforj net product revenue $7.7M in first five weeks of U.S. launch.
- Net loss $94.2M ($1.10/share) for Q4 2024 vs $72.5M ($1.00) in Q4 2023; full year net loss $318.8M ($3.72).
- Cash, equivalents and investments $692.4M; expects current resources to fund to profitability.
- Launched Niktimvo in Jan 2025 with Incyte; $350M royalty funding from Royalty Pharma on Niktimvo sales.
- sNDA for revumenib in R/R mNPM1 AML expected Q2 2025 based on positive AUGMENT-101 data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017025030392/0000950170-25-030392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017025030392/sndx-20250303.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-030392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer